The trial involved 807 adult patients with IBS who were randomly assigned to either various doses of eluxadoline or an oral placebo. Researchers tracked the clinical response to the treatments for 14 weeks with week four being the primary endpoint.
The patients who took 100mg of the drug had global symptom improvement at eight and 12 weeks. Quality of life scores significantly improved, as well. Events, such as abdominal pain, constipation, nausea and vomiting, occurred most often with patients who received 200 mg doses.
More Articles on Gastroenterology:
Mailed Invitations May Increase Screenings for Noninvasive Tests
Study: Obese Black Americans Less Likely to Undergo Bariatric Surgery Than Whites
Increased Demand to Boost Endoscopy Global Market to $5.8B Value by 2018
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
